C21 Investments Inc. (CXXIF)
Healthcare · OQX
Price as at 30 Sept 2026, 17:26 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
C21 Investments Inc. trades at $0.27, which is 17% above the $0.22 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 23 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
CXXIF dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
About C21 Investments Inc.
C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States. The company offers CO2, live resin, distillate, CBD cured resin, and CBD CO2 vaporizer pens; live, cured, and CBD cured resin extracts; bulk and packaged flowers; edibles; pre-rolls; tinctures; and topicals. It also provides payroll and benefits services. The company offers its products through wholesale and retail channels. The company was formerly known as Curlew Lake Resources Inc. and changed its name to C21 Investments Inc. in November 2017. C21 Investments Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada. As of August 21, 2026, C21 Investments Inc. operates as a subsidiary of Vireo Growth Inc.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
CXXIF passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
CXXIF peers
The largest companies in the same industry (Drug Manufacturers - Specialty & Generic), then in the same sector.
- TKPHF Takeda Pharmaceutical Company Limited
- GALDY Galderma Group AG
- JHPCY JHPCY
- HLNCF Haleon plc
- TEVA Teva Pharmaceutical Industries Limited
- UTHR United Therapeutics Corporation
- VTRS Viatris Inc.
- NBIX Neurocrine Biosciences, Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is C21 Investments Inc. (CXXIF) undervalued?
Against our fair value estimate of $0.22, CXXIF at $0.27 is 17% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Where does SteadyShares get its CXXIF data?
Fundamentals for CXXIF come from company filings and exchange data, as listed on OQX; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:26 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CXXIF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.